Table 1 Basal clinical characteristics in SGLT2i and control group
Variable | SGLT2i (n = 30) | Control (n = 22) | p value |
|---|---|---|---|
Female, n (%) | 13 (43%) | 10 (45%) | 0.88 |
Age (years) | 65.7 ± 8.7 | 68.2 ± 8.5 | 0.32 |
Arterial hypertension | 18 (60%) | 16 (73%) | 0.34 |
Smokers | 6 (20%) | 1 (4%) | 0.22 |
Dyslipidaemia | 16 (53%) | 12 (54%) | 0.93 |
Coronary disease | 3 (10%) | 1 (4%) | 0.33 |
Metformin | 23 (77%) | 18 (82%) | 0.74 |
DPP4 inhibitors | 8 (27%) | 7 (32%) | 0.68 |
Insulin | 9 (30%) | 5 (23%) | 0.56 |
RAAS inhibitors | 21 (70%) | 17 (77%) | 0.56 |
Beta-blockers | 3 (10%) | 2 (9%) | 0.89 |
Aldosterone antagonist | 2 (7%) | 0 (0%) | 0.50 |
GF ≥ 60 ml/min/1.73 m2 | 12 (43%) | 11 (50%) | 0.24 |
Glycated haemoglobin | 7.78 ± 0.94 | 6.97 ± 0.44 | 0.002 |
Diabetes duration (months) | 87 ± 97 | 128 ± 105 | 0.14 |
BMI (kg/m2) | 30.5 ± 6.8 | 28.9 ± 4.7 | 0.33 |
GF (ml/min/1.73 m2) | 92.6 ± 40.8 | 86.7 ± 28.9 |